Catalysts for Janssen Biotech Inc
140 tracked
Dec 19, 2023
approval
ERLEADA (APALUTAMIDE) — FDA approval
apalutamide
→
Nov 16, 2023
approval
SIMPONI (GOLIMUMAB) — FDA approval
Janssen Biotech Inc
→
Nov 16, 2023
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Nov 16, 2023
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Aug 11, 2023
approval
AKEEGA (ABIRATERONE ACETATE) — FDA approval
(abiraterone acetate + niraparib)
→
Aug 9, 2023
approval
TALVEY (TALQUETAMAB-TGVS) — FDA approval
talquetamab
→
Aug 9, 2023
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Jun 29, 2023
approval
TREMFYA (GUSELKUMAB) — FDA approval
guselkumab
→
Mar 30, 2023
approval
SIMPONI (GOLIMUMAB) — FDA approval
Janssen Biotech Inc
→
Mar 20, 2023
approval
BALVERSA (ERDAFITINIB) — FDA approval
erdafitinib
→
Mar 6, 2023
approval
STELARA (USTEKINUMAB) — FDA approval
ustekinumab
→
Feb 17, 2023
approval
ERLEADA (APALUTAMIDE) — FDA approval
apalutamide
→
Jan 11, 2023
approval
BALVERSA (ERDAFITINIB) — FDA approval
erdafitinib
→
Nov 8, 2022
approval
ERLEADA (APALUTAMIDE) — FDA approval
apalutamide
→
Nov 8, 2022
approval
ERLEADA (APALUTAMIDE) — FDA approval
apalutamide
→
Nov 4, 2022
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Nov 2, 2022
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Oct 25, 2022
approval
TECVAYLI (TECLISTAMAB-CQYV) — FDA approval
teclistamab
→
Jul 29, 2022
approval
STELARA (USTEKINUMAB) — FDA approval
ustekinumab
→
Apr 27, 2022
approval
BALVERSA (ERDAFITINIB) — FDA approval
erdafitinib
→
Apr 27, 2022
approval
BALVERSA (ERDAFITINIB) — FDA approval
erdafitinib
→
Apr 26, 2022
approval
ERLEADA (APALUTAMIDE) — FDA approval
apalutamide
→
Jan 21, 2022
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Dec 21, 2021
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Nov 30, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Sep 7, 2021
approval
ERLEADA (APALUTAMIDE) — FDA approval
apalutamide
→
Jul 14, 2021
approval
ERLEADA (APALUTAMIDE) — FDA approval
apalutamide
→
Jul 9, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
May 21, 2021
approval
RYBREVANT (AMIVANTAMAB-VMJW) — FDA approval
amivantamab
→
Mar 12, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→